{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T12:05:06Z","timestamp":1772107506299,"version":"3.50.1"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"36","license":[{"start":{"date-parts":[[2019,3,28]],"date-time":"2019-03-28T00:00:00Z","timestamp":1553731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100008333","name":"University of Alabama at Birmingham","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008333","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Birmingham VA Medical Center"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,9,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Gout is associated with a higher risk of atrial fibrillation (AF). Comparative effectiveness of allopurinol or febuxostat for reducing the AF risk is unknown, which was our study\u2019s main objective.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>We used the 5% Medicare Beneficiary cohort (\u226565\u2009years) from 2006 to 2012 to identify people with a new filled prescription for allopurinol or febuxostat, with a baseline period of 365\u2009days without respective medication and without AF. We used 5:1 propensity-matched Cox regression analyses to assess whether allopurinol use differed from febuxostat use regarding the hazard ratio (HR) of incident AF. We found 25\u00a0732 eligible episodes in 23\u00a0135 beneficiaries. Of these, 2311 incident allopurinol or febuxostat use episodes (9%) ended in incident AF with crude incidence rates of 8.0 and 10.5 per 100 person-years, respectively. In propensity-matched analyses, compared with allopurinol, febuxostat was associated with higher HR of AF, 1.25 [95% confidence interval (CI) 1.05\u20131.48]. Compared with allopurinol &amp;lt;200\u2009mg\/day, febuxostat 80\u2009mg\/day was associated with significantly higher HR of AF, 1.62 (95% CI 1.16\u20132.27), but not febuxostat 40\u2009mg\/day or higher allopurinol doses. Compared with 1\u2013180\u2009days of allopurinol use, febuxostat use for 1\u2013180\u2009days was associated with significantly higher HR of AF, 1.36 (95% CI 1.10\u20131.67), but longer durations were not.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Febuxostat was associated with a higher risk of AF compared with allopurinol in older adults. Increased AF risk was noted with febuxostat 80\u2009mg\/day dose and was most evident in the first 6 months of use. These findings need replication.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehz154","type":"journal-article","created":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T20:14:42Z","timestamp":1551471282000},"page":"3046-3054","source":"Crossref","is-referenced-by-count":33,"title":["Comparative effectiveness of allopurinol and febuxostat for the risk of atrial fibrillation in the elderly: a propensity-matched analysis of Medicare claims data"],"prefix":"10.1093","volume":"40","author":[{"given":"Jasvinder A","family":"Singh","sequence":"first","affiliation":[{"name":"VA Medical Center Medicine Service, , 700 19th St S, Birmingham, AL, USA"},{"name":"The University of Alabama at Birmingham Department of Medicine at The School of Medicine, , 510 20th Street South, Faculty Office Tower 805B, Birmingham, AL, USA"},{"name":"University of Alabama at Birmingham Division of Epidemiology at School of Public Health, The , 1720 Second Ave. South, Birmingham, AL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John D","family":"Cleveland","sequence":"additional","affiliation":[{"name":"The University of Alabama at Birmingham Department of Medicine at The School of Medicine, , 510 20th Street South, Faculty Office Tower 805B, Birmingham, AL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,3,28]]},"reference":[{"key":"2022102608154848400_ehz154-B1","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2014.03.022","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society","volume":"64","author":"January","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2022102608154848400_ehz154-B2","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.113.005119","article-title":"Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study","volume":"129","author":"Chugh","year":"2014","journal-title":"Circulation"},{"key":"2022102608154848400_ehz154-B3","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1093\/eurheartj\/eht280","article-title":"Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060","volume":"34","author":"Krijthe","year":"2013","journal-title":"Eur Heart J"},{"key":"2022102608154848400_ehz154-B4","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","article-title":"Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study","volume":"285","author":"Go","year":"2001","journal-title":"JAMA"},{"key":"2022102608154848400_ehz154-B5","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/eurheartj\/ehi825","article-title":"Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study","volume":"27","author":"Heeringa","year":"2006","journal-title":"Eur Heart J"},{"key":"2022102608154848400_ehz154-B6","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1161\/01.CIR.0000140263.20897.42","article-title":"Lifetime risk for development of atrial fibrillation: the Framingham Heart Study","volume":"110","author":"Lloyd-Jones","year":"2004","journal-title":"Circulation"},{"key":"2022102608154848400_ehz154-B7","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/eurheartj\/ehq278","article-title":"Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC)","volume":"31","author":"Camm","year":"2010","journal-title":"Eur Heart J"},{"key":"2022102608154848400_ehz154-B8","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"2022102608154848400_ehz154-B9","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1161\/01.CIR.98.10.946","article-title":"Impact of atrial fibrillation on the risk of death: the Framingham Heart Study","volume":"98","author":"Benjamin","year":"1998","journal-title":"Circulation"},{"key":"2022102608154848400_ehz154-B10","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.hrthm.2014.04.003","article-title":"Association between serum uric acid and atrial fibrillation: a systematic review and meta-analysis","volume":"11","author":"Tamariz","year":"2014","journal-title":"Heart Rhythm"},{"key":"2022102608154848400_ehz154-B11","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.ijcard.2015.02.038","article-title":"Hyperuricemia is independently associated with increased risk of atrial fibrillation: a meta-analysis of cohort studies","volume":"184","author":"Xu","year":"2015","journal-title":"Int J Cardiol"},{"key":"2022102608154848400_ehz154-B12","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/art.30520","article-title":"Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008","volume":"63","author":"Zhu","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2022102608154848400_ehz154-B13","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1177\/2047487313514895","article-title":"Increased cardiovascular mortality associated with gout: a systematic review and meta-analysis","volume":"22","author":"Clarson","year":"2015","journal-title":"Eur J Prev Cardiol"},{"key":"2022102608154848400_ehz154-B14","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1136\/annrheumdis-2015-208161","article-title":"Risk of incident atrial fibrillation in gout: a cohort study","volume":"75","author":"Kim","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2022102608154848400_ehz154-B15","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/rheumatology\/kev418","article-title":"Impact of gout on the risk of atrial fibrillation","volume":"55","author":"Kuo","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"2022102608154848400_ehz154-B16","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/FJC.0000000000000313","article-title":"Oxidant and inflammatory mechanisms and targeted therapy in atrial fibrillation: an update","volume":"66","author":"Gutierrez","year":"2015","journal-title":"J Cardiovasc Pharmacol"},{"key":"2022102608154848400_ehz154-B17","doi-asserted-by":"crossref","first-page":"e001886","DOI":"10.1161\/JAHA.115.001886","article-title":"Oxidative stress biomarkers and incidence of postoperative atrial fibrillation in the Omega-3 Fatty Acids for Prevention of Postoperative Atrial Fibrillation (OPERA) trial","volume":"4","author":"Wu","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"2022102608154848400_ehz154-B18","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/jce.12560","article-title":"Defining the role of oxidative stress in atrial fibrillation and diabetes","volume":"26","author":"Ziolo","year":"2015","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2022102608154848400_ehz154-B19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00210-016-1320-9","article-title":"Perspectives and challenges of antioxidant therapy for atrial fibrillation","volume":"390","author":"Gasparova","year":"2017","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"2022102608154848400_ehz154-B20","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/0006-291X(87)91112-0","article-title":"Role of xanthine oxidase inhibitor as free radical scavenger: a novel mechanism of action of allopurinol and oxypurinol in myocardial salvage","volume":"148","author":"Das","year":"1987","journal-title":"Biochem Biophys Res Commun"},{"key":"2022102608154848400_ehz154-B21","first-page":"94","article-title":"Effect of allopurinol on oxidative stress and hypoxic adaptation response during surgical correction of tetralogy of fallot","volume":"45","author":"Rachmat","year":"2013","journal-title":"Acta Med Indones"},{"key":"2022102608154848400_ehz154-B22","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White","year":"2018","journal-title":"N Engl J Med"},{"key":"2022102608154848400_ehz154-B23","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1136\/annrheumdis-2015-209008","article-title":"Allopurinol and the risk of atrial fibrillation in the elderly: a study using Medicare data","volume":"76","author":"Singh","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2022102608154848400_ehz154-B24","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00296-013-2857-2","article-title":"As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout","volume":"34","author":"Tausche","year":"2014","journal-title":"Rheumatol Int"},{"key":"2022102608154848400_ehz154-B25","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jjcc.2014.12.017","article-title":"Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD)","volume":"66","author":"Sezai","year":"2015","journal-title":"J Cardiol"},{"key":"2022102608154848400_ehz154-B26","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/0895-4356(93)90103-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives","volume":"46","author":"Romano","year":"1993","journal-title":"J Clin Epidemiol"},{"key":"2022102608154848400_ehz154-B27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/pds.3334","article-title":"The incident user design in comparative effectiveness research","volume":"22","author":"Johnson","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2022102608154848400_ehz154-B28","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/pds.2317","article-title":"A systematic review of validated methods for identifying atrial fibrillation using administrative data","volume":"21(Suppl 1)","author":"Jensen","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2022102608154848400_ehz154-B29","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ahj.2014.09.014","article-title":"Accuracy and validation of an automated electronic algorithm to identify patients with atrial fibrillation at risk for stroke","volume":"169","author":"Navar-Boggan","year":"2015","journal-title":"Am Heart J"},{"key":"2022102608154848400_ehz154-B30","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1080\/01621459.1989.10478874","article-title":"The robust inference for the Cox proportional hazards model","volume":"84","author":"Lin","year":"1989","journal-title":"J Am Stat Assoc"},{"key":"2022102608154848400_ehz154-B31","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1076-7460.2005.02278.x","article-title":"The epidemiology of atrial fibrillation in elderly persons: the tip of the iceberg","volume":"14","author":"Go","year":"2005","journal-title":"Am J Geriatr Cardiol"},{"key":"2022102608154848400_ehz154-B32","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0002-9343(99)80348-9","article-title":"The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study","volume":"98","author":"Krahn","year":"1995","journal-title":"Am J Med"},{"key":"2022102608154848400_ehz154-B33","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1124\/pr.58.1.6","article-title":"Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol","volume":"58","author":"Pacher","year":"2006","journal-title":"Pharmacol Rev"},{"key":"2022102608154848400_ehz154-B34","doi-asserted-by":"crossref","first-page":"9090","DOI":"10.1016\/S0021-9258(19)52512-1","article-title":"Studies on the oxidative half-reaction of xanthine oxidase","volume":"256","author":"Hille","year":"1981","journal-title":"J Biol Chem"},{"key":"2022102608154848400_ehz154-B35","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2147\/VHRM.S4265","article-title":"Role of urate, xanthine oxidase and the effects of allopurinol in vascular oxidative stress","volume":"5","author":"George","year":"2009","journal-title":"Vasc Health Risk Manag"},{"key":"2022102608154848400_ehz154-B36","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N Engl J Med"},{"key":"2022102608154848400_ehz154-B37","author":"Herrington"},{"key":"2022102608154848400_ehz154-B38","first-page":"10","article-title":"Allopurinol protection of hepatic nuclear function during hemorrhagic shock","volume":"25","author":"Lazarus","year":"1974","journal-title":"Surg Forum"},{"key":"2022102608154848400_ehz154-B39","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1152\/physrev.00031.2009","article-title":"Pathophysiological mechanisms of atrial fibrillation: a translational appraisal","volume":"91","author":"Schotten","year":"2011","journal-title":"Physiol Rev"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/40\/36\/3046\/46638337\/eurheartj_40_36_3046.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/40\/36\/3046\/46638337\/eurheartj_40_36_3046.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T08:19:03Z","timestamp":1666772343000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/40\/36\/3046\/5421316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,28]]},"references-count":39,"journal-issue":{"issue":"36","published-online":{"date-parts":[[2019,3,28]]},"published-print":{"date-parts":[[2019,9,21]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehz154","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,9,21]]},"published":{"date-parts":[[2019,3,28]]}}}